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ABSTRACT
Hepatitis C virus (HCV) is a leading cause of liver diseases including the 
development of hepatocellular carcinoma (HCC). Particularly, core protein has been 
involved in HCV-related liver pathologies. However, the impact of HCV core on signaling 
pathways supporting the genesis of HCC remains largely elusive. To decipher the 
host cell signaling pathways involved in the oncogenic potential of HCV core, a global 
quantitative phosphoproteomic approach was carried out. This study shed light on 
novel differentially phosphorylated proteins, in particular several components involved 
in translation. Among the eukaryotic initiation factors that govern the translational 
machinery, 4E-BP1 represents a master regulator of protein synthesis that is associated 
with the development and progression of cancers due to its ability to increase protein 
expression of oncogenic pathways. Enhanced levels of 4E-BP1 in non-modified and 
phosphorylated forms were validated in human hepatoma cells and in mouse primary 
hepatocytes expressing HCV core, in the livers of HCV core transgenic mice as well as in 
HCV-infected human primary hepatocytes. The contribution of HCV core in carcinogenesis 
and the status of 4E-BP1 expression and phosphorylation were studied in HCV core/
Myc double transgenic mice. HCV core increased the levels of 4E-BP1 expression and 
phosphorylation and significantly accelerated the onset of Myc-induced tumorigenesis 
in these double transgenic mice. These results reveal a novel function of HCV core in 
liver carcinogenesis potentiation. They position 4E-BP1 as a tumor-specific target of HCV 
core and support the involvement of the 4E-BP1/eIF4E axis in hepatocarcinogenesis.
                                                       Research Paper
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the sixth most 
prevalent cancer and the second most common cause 
of cancer-related deaths worldwide. Its incidence is 
still increasing [1]. Hepatitis C Virus (HCV) infection 
is one of the major etiologies of HCC. Major progress 
in HCV therapy now leads to envisage the eradication 
of HCV infection in a near future. However, these 
new treatments do not directly interfere with liver 
carcinogenesis and therefore many patients already at 
the stage of HCV-induced cirrhosis will still develop 
HCC. Furthermore, there is accumulating evidence that 
there are common pathways and related mechanisms 
that likely account for viral and non-viral pathogenesis 
of cancers [2]. Thus, elucidating the pathways 
implicated in the progression of HCV-induced liver 
disease and HCC is still an unmet need for developing 
novel therapeutic approaches. 
The involvement of viral and host factors in the 
progression of HCV-induced liver disease is intricate. 
It has been suggested that HCV-encoded proteins are 
directly involved in the tumorigenic process through 
interaction with a number of host factors and signaling 
pathways. Extensive studies have suggested that HCV 
core protein binds several cellular proteins and plays 
a major role in HCV-induced liver pathologies by 
modulating multiple cellular processes. Among them, we 
have reported that HCV core protein inhibits the canonic 
TGF-β signaling pathway [3] and shifts its biological 
responses from tumor suppression to tumor progression by 
decreasing hepatocyte apoptosis and increasing epithelial 
mesenchymal transition (EMT) [4]. Strikingly, an HCV 
core sequence isolated from an HCC nodule was more 
potent to inhibit TGF-β signaling than a core sequence 
isolated from the adjacent non-tumor tissue, highlighting 
the ability of HCV core variants to display different 
biological host responses [4]. 
Several studies conducted on transgenic animal 
models have reported that HCV core expression led to 
either no particular phenotype [5], steatosis [6, 7], insulin 
resistance [8, 9], modulation of apoptosis [10, 11] or 
even HCC development [12]. This is consistent with the 
notion that these various observations might be correlated 
with HCV genotype, mouse genetic background [13], or 
HCV core levels related to the chosen promoter as well 
as with core sequences used in the different studies. The 
establishment of transgenic mouse models expressing core 
sequences isolated from tumor or non-tumor nodules of 
the same patient would be an invaluable tool to investigate 
the pathological potential of these HCV core variants and 
the molecular basis downstream.
To decipher the molecular events involved in the 
oncogenic potential of HCV core, a global quantitative 
phosphoproteomic approach of HCV core expressing 
cells represents a highly valuable tool to investigate 
the activation or repression of host cell signaling 
transduction pathways. Indeed, no data are available 
on the global profile of the HCV core regulated 
phosphoproteome. We here report the identification of a 
panel of proteins phosphorylated in HCV core expressing 
cells involved in metabolism, cell death, protein transport 
and cellular component organization as well as in the 
regulation of translation. In particular, we demonstrated 
that HCV core activates a pathway increasing the 
phosphorylated level of the key translation factor 
eukaryotic translation initiation factor 4E-binding protein 
1 (4E-BP1) in primary human and mouse hepatocytes as 
well as in HCV core transgenic mouse livers. We also 
report that HCV core is able to potentiate Myc-induced 
tumor development in double transgenic mice and 
4E-BP1 might be responsible for this acceleration of 
tumor progression.
RESULTS
Quantitative phosphoproteomic analysis of 
hepatoma cell line expressing HCV core protein
A SILAC-based phosphoproteomic approach 
was applied to unveil the signal transduction pathways 
modulated by HCV core protein. Hence, HuH7 and HuH7 
expressing HCV core protein were cultured in SILAC 
media for metabolic labeling. Cells were lysed and the 
protein lysates were pooled in equimolar ratio prior to 
in-solution trypsin digestion. Phosphopeptides were 
further selectively enriched using an immobilized metal 
affinity chromatography (IMAC) resin and then analyzed 
by liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS). The strategy exhibited the 
major advantage to allow simultaneously identification 
and accurate quantification of phosphorylated proteins 
under the different conditions. This state-of-the-art 
proteomic approach was applied to the cellular models 
in three independent SILAC experiments and led to the 
identification of 7 proteins down-phosphorylated and 24 
proteins hyper-phosphorylated in HCV core expressing 
cells (Table 1). In addition, 16 out of the 35 differentially 
phosphorylated peptides exhibited a modulation of 
phosphorylation within the (Ser/Thr)-Pro motif, broadly 
recognized as potential MAP kinase and mTORC1 
target sites [14], indicating that the (Ser/Thr)-Pro motif 
is essential for dynamic signaling transduction in HCV-
core-expressing cells [15]. A functional network was built 
by investigating the functions of the identified proteins 
into Go Elite database and visualized in Cytoscape 
program. This approach revealed that the phosphoproteins 
modulated by HCV core were prominently involved 
in metabolism (carbohydrate and lipid biosynthetic 
processes), insulin receptor signaling, protein transport, 
cell death, cellular component organization and 
translation (Figure 1). 
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Table 1: Proteins and peptides with modulated phosphorylation in HuH7 cells expressing HCV 
core protein
Ratio  cT/ WT
Gene 
Names
Accession 
number Protein Names Modified sequence
Probabilities of 
phosphorylation 
on STY
Phosphorylated 
position S1 S2 S3
BCKDHA F5H5P2 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial
IGHHS(ph)T(ph)
SDDSSAYRSVDEVNYWDKQDHPISR S(0.424)T(0.424) S371/T372 2.58 _ _
IGHHS(ph)TSDDSSAY(ph)
RSVDEVNYWDK
S(0.748)
Y(0.283) S371/Y379 _ 2.36 1.54
SNTB1 Q13884 Beta-1-syntrophin LVHSGPGKGS(ph)PQAGVDLSFATR S(1) S389 3.8 1.67 1.83
SH3KBP1 Q96B97 SH3 domain-containing kinase-binding protein 1 S(ph)IEVENDFLPVEK S(1) S230 2.05 _ 2.08
RPS6KA3; 
RPS6KA6 P51812
Ribosomal protein S6 kinase 
alpha-3
KAYS(ph)FCGTVEYMAPEVVNRR S(0.987) S227 _ 2.57 _
TPKDS(ph)PGIPPSANAHQLFR S(0.998) S369 1.5 3.98 1.77
SDAD1 Q9NVU7 Protein SDA1 homolog YIEIDS(ph)DEEPRGELLSLR S(1) S585 2.11 1.7 1.5
FAM122A Q96E09 Protein FAM122A RIDFIPVS(ph)PAPS(ph)PTR S(1)S(0.99) S143/S147 _ 2.03 1.59
EIF4EBP1 Q13541 Eukaryotic translation initiation factor 4E-binding protein 1
RVVLGDGVQLPPGDYSTT(ph)
PGGTLFSTT(ph)PGGTR
T(0.968)
T(0.493) T37/T46 1.15 2.95 2.23
EIF4EBP2 Q13542 Eukaryotic translation initiation factor 4E-binding protein 2
TVAISDAAQLPHDYCTT(ph)
PGGTLFSTT(ph)PGGTR T(0.5)T(0.469) T37/T46 _ 1.96 1.81
SRP72 O76094 Signal recognition particle 72 kDa protein
TVSSPPTS(ph)PRPGS(ph)
AATVSASTSNIIPPR S(0.31)S(0.354) S625/S630 _ 2.03 1.81
EHBP1 Q8NDI1 EH domain-binding protein 1
DLSTS(ph)PKPSPIPS(ph)PVLGR S(0.739)S(0.998) S428/S436 1.67 _ 2
DLSTS(ph)PKPS(ph)PIPS(ph)PVLGR S(0.401)S(1)S(1) S428/S432/S436 1.52 2.29 2
TMPO P42167 Lamina-associated polypeptide 2, isoforms beta/gamma
GPPDFS(ph)S(ph)DEEREPT(ph)
PVLGSGAAAAGR S(1)S(1)T(0.987) S66/S67/T74 _ 2.08 1.52
SEC16A J3KNL6 Protein transport protein Sec16A GSVSQPS(ph)T(ph)PS(ph)PPKPTGIFQTSANSSFEPVK
S(0.715)T(0.715)
S(0.81) S592/T593/S595 _ 2.97 1.88
TPI1 P60174 Triosephosphate isomerase KQS(ph)LGELIGTLNAAK S(1) S58 1.63 2.41 2.79
NUCKS1 Q9H1E3
Nuclear ubiquitous casein and 
cyclin-dependent kinase substrate 
1
KVVDYS(ph)
QFQESDDADEDYGRDSGPPTK S(0.526) S14 _ 2.2 1.79
VVDYSQFQES(ph)
DDADEDYGRDSGPPTK S(0.992) S19 _ 2.07 1.82
FAM21A; 
FAM21B Q641Q2
WASH complex subunit 
FAM21A;WASH complex subunit 
FAM21B
ASALLFS(ph)S(ph)
DEEDQWNIPASQTHLASDSR S(0.999)S(1) S619/S620 _ 1.51 2.69
CDS2 O95674 Phosphatidate cytidylyltransferase 2
VAHEPVAPPEDKES(ph)
ESEAKVDGET(ph)ASDSESR S(0.714)T(0.537) S21/T31 _ 1.59 2.39
MAP4 E7EVA0 Microtubule-associated protein 4 DMES(ph)PTKLDVTLAK S(0.995) S297 _ 2.27 2.2
EIF4B E7EX17 Eukaryotic translation initiation factor 4B
SLENETLNKEEDCHSPT(ph)
SKPPKPDQPLK T(0.917) T466 _ 1.63 3.39
SYAP1 Q96A49 Synapse-associated protein 1 EQDLPLAEAVRPKT(ph)PPVVIK T(1) T248 _ 2.37 1.52
HMGCS1 Q01581 Hydroxymethylglutaryl-CoA synthase, cytoplasmic
RPTPNDDTLDEGVGLVHSNIATEHIPS(ph)
PAK S(0.999) S495 1.52 _ 3.82
EPB41L2 O43491 Band 4.1-like protein 2 EVRS(ph)PTKAPHLQLIEGK S(1) S598 _ 1.77 2.16
EPPK1 P58107 Epiplakin RQVS(ph)ASELHTSGILGPETLR S(0.918) S2716 1.71 2 _
ABCF1 Q8NE71 ATP-binding cassette sub-family F member 1 KLS(ph)VPT(ph)S(ph)DEEDEVPAPKPR S(1)T(1)S(1) S105/T108/S109 2.69 2.12 _
HSPB1 P04792 Heat shock protein beta-1 GPS(ph)WDPFRDWYPHSR S(1) S15 4.21 3.02 2.99
TJP1 G3V1L9 Tight junction protein ZO-1 VQIPVSRPDPEPVS(ph)DNEEDSY(ph)DEEIHDPR
S(0.963)
Y(0.783) S125/Y132 0.54 0.55 _
HNF1B P35680 Hepatocyte nuclear factor 1-beta GRLS(ph)GDEGS(ph)EDGDDYDTPPILK S(1)S(1) S75/S80 0.39 0.38 _
EPS8L3 Q8TE67-3
Epidermal growth factor receptor 
kinase substrate 8-like protein 3 RS(ph)SS(ph)PEDPERDEEVLNHVLR S(0.667)S(0.667) S229/S231 0.46 0.4 _
LRP2 P98164 Low-density lipoprotein receptor-related protein 2 ES(ph)VAATPPPS(ph)PSLPAKPKPPSR S(0.942)S(0.958) S4608/S4616 0.2 0.26 _
RAB11FIP1 Q6WKZ4 Rab11 family-interacting protein 1 HLFSS(ph)TENLAAGSWKEPAEGGGLSSDR S(0.805) S357 0.31 0.46 _
KRT18 P05783 Keratin, type I cytoskeletal 18 STSFRGGMGS(ph)GGLATGIAGGLAGMGGIQNEK S(0.776) S60 _ 0.32 0.55
SQSTM1 Q13501 Sequestosome-1 KIALESEGRPEEQMES(ph)DNCS(ph)GGDDDWTHLSSK S(0.997)S(0.998) S328/S332 _ 0.54 0.41
The table encompasses the genes, protein names and their accession numbers according to the UniProt-SwissProt database. In the peptide sequences, (ph) 
after S/T/Y residue indicates the phosphorylated status. The probability for the site of phosphorylation was calculated by MaxQuant. The study was performed 
in biological triplicate (S1/S2/S3) and Phosphorylated peptides were considered to be significantly regulated when exhibiting an abundance ratio core/WT 
exceeding mean + 1.96 standard deviation in at least two replicates. 
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HCV core protein enhances the level of 
phosphorylated 4E-BP1 in human hepatoma 
cells and primary hepatocytes
Among the proteins appearing substantially hyper-
phosphorylated in HCV core protein expressing cells 
compared to the control, several components involved 
in translation were identified such as the eukaryotic 
translation initiation factor 4B (EIF4B) and the eukaryotic 
translation initiation factors 4E-binding protein 1 
(4E-BP1) and 2 (4E-BP2). These proteins play a critical 
role in protein synthesis control [16] and their deregulation 
is associated with the development and progression 
of cancers because components of the translational 
machinery function at the point of convergence of 
deregulated cell signaling pathways. 
We further focused on 4E-BP1 phosphorylation 
because this event is critical in causing 4E-BP1 
dissociation from eIF4E, which leaves 4E available to form 
the translationally active eIF4F complex and then results 
in switching on mRNA translation, which may contribute 
to changes in gene expression associated with malignant 
transformation [17]. To validate the phosphoproteomic 
findings and evaluate the state of 4E-BP1 phosphorylation 
on Thr 37/46, lysates prepared from HuH7 WT cells and 
HuH7 cells stably expressing core protein variants either 
isolated from tumor cT or non-tumor cirrhotic (cNT) 
areas, were analyzed by immunoblotting using an antibody 
that recognizes exclusively the dual phosphorylation 
on the residues Thr37/46. The amount of 4E-BP1 
phosphorylated on Thr37 and Thr46 was significantly 
higher in HuH7 cT and cNT cells compared to HuH7 WT 
cells (Figure 2A and 2B), which matched and validated 
the aforementioned SILAC-based phosphoproteomics 
findings. The same increase in phosphorylated 4E-BP1 
was observed with both core variants although the cNT 
was much more expressed than the cT (Figure 2B). In 
accordance with numerous previous studies, 4E-BP1 and 
its phosphorylated form are detected as multiple bands on 
gels in the vicinity of 20 kDa [18]. Moreover, an increased 
amount of phosphorylated 4E-BP1 was associated with an 
enhancement of 4E-BP1 expression in agreement with 
previously reported studies [19]. 4E-BP1 phosphorylation 
on Thr37/46 primes its subsequent phosphorylation on 
Ser65 and Thr70, decreasing its affinity for eIF4E, which 
allows eIF4G and associated factors to bind to eIF4E 
[17]. Therefore, these potential 4E-BP1 phosphorylation 
sites were investigated by immunoblotting using specific 
antibodies. As shown in Figure 2C and 2D, an increase of 
phosphorylated 4E-BP1 at Ser65 and Thr70 was observed 
in HuH7 cells expressing both HCV core cT and cNT 
compared to HuH7 WT.
To further substantiate the assumption of the HCV 
core protein-driven increase of phosphorylated 4E-BP1, 
Figure 1: Functional clustering of the differentially modulated phosphoproteins identified by phosphoproteomics. Red 
and green circles correspond to up- and down-phosphorylated proteins, respectively.
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human HuH9.13 cell line, harboring HCV NS3-NS5B 
subgenomic replicon, was herein used together with controls 
cured from the replicon. Interestingly but unexpectedly, 
HuH9.13 exhibited a drastically lower level of phospho-
4E-BP1 on Thr37/46, Ser65 and Thr70 compared to HuH7 
cT/cNT in immunoblot analysis (Figure 2A–2D). Whereas 
previous studies have shown that NS5A expressing cells 
(NS5A-HuH7.5) induce 4E-BP1 hyper-phosphorylation 
[20], a very weak signal was detected with the HuH9.13 
used in this study, despite NS5A expression (Figure 2A–2D). 
Moreover, the increase in 4E-BP1 phosphorylation was also 
observed in HuH7.5 cells expressing the entire replicon 
(Figure 2E), confirming the efficacy of HCV core to 
promote 4E-BP1 phosphorylation in presence of all HCV 
proteins. Similarly, phospho-4E-BP1 levels were enhanced 
in JFH1-infected HuH7.5.1 in comparison with mock 
cells (Figure 2F). Notably, the enhancement in 4E-BP1 
phosphorylation was likewise retrieved in primary human 
hepatocytes infected with JFH1 (Figure 2G). Strikingly 
fold changes of phospho-4EBP1 normalized to 4E-BP1 
expression were not significantly different in hepatoma 
cell lines, however it turned significant in primary human 
hepatocytes (Figure 2B, 2G). This observation could be 
linked to the derivation of the HuH7 cell line from an HCC 
since it has been reported that 4E-BP1 phosphorylation was 
already increased in HCC tissues [19]. 
Taken together, these data experimentally confirmed 
the quantitative phosphoproteomic findings and strongly 
support the hypothesis that both HCV core variants cT and 
cNT induce 4E-BP1 dual phosphorylation in a hepatoma 
cell line. Importantly this effect was also observed in 
HCV-infected primary human hepatocytes.
HCV core promotes 4E-BP1 phosphorylation  
in vivo
The above-mentioned in vitro observations raised 
the question of whether HCV core protein could drive an 
increase in the level of phosphorylated 4E-BP1 in vivo. 
Therefore, we used transgenic mice harboring two core 
variant sequences cT and cNT [4]. These mice did not 
exhibit demonstrable deficits in growth or development 
and no cellular inflammatory infiltrate was evident in their 
livers. Interestingly, when liver proteins extracted from 
these transgenic mice were analyzed for core by Western 
blot, a strong signal was detected at the expected 20 kDa 
in cNT, whereas a faint signal was visible in cT. To check 
the transcription level of HCV core, RNA was isolated 
from 3 different WT, cT and cNT transgenic mouse livers, 
reverse transcribed into cDNA, amplified and quantified 
by qPCR for HCV core gene. The same transcription level 
of HCV core messenger in cT and cNT mouse livers was 
detected (Supplementary Figure 1). Thus, the low protein 
level of HCV core cT could be related to its instability 
and its further degradation. This hypothesis was confirmed 
by a significant increase of cT protein expression in cells 
treated with MG132, a proteasome inhibitor, which 
effectively blocks the proteolytic activity of the 26S 
proteasome complex (Supplementary Figure 1).
To study the 4E-BP1 phosphorylation status in the 
liver of these transgenic animals, Western blot assays 
were performed on different 9-month-old mouse liver 
protein lysates and a representative example of protein 
extracts from four mice per group is shown in Figure 3. 
In agreement with in vitro data, immunoblotting 
of lysates from cT and cNT mouse liver showed a 
significant HCV core protein dependent increase of 
4E-BP1 phosphorylation on Thr37/46 in comparison with 
the WT (Figure 3A and 3B). Of note, the observations 
made in vivo not only indicated an increased amount 
of phosphorylated 4E-BP1 at constant phosphorylation 
stoichiometry as it was the case in vitro; this time cT 
and cNT also enhanced the phosphorylation level of the 
protein 4E-BP1. Furthermore, immunohistochemical 
staining of p4E-BP1 was performed on transgenic mouse 
livers. Figure 3C shows the increase in p4E-BP1 in cT 
and cNT mouse livers compared to the WT. Next, it was 
relevant to explore the phosphorylation state of 4E-BP1 
in primary cultured mouse hepatocytes isolated from 
WT and transgenic mouse livers expressing either HCV 
core protein variant cT or cNT. To this end, we compared 
the phosphorylation changes of 4E-BP1 by Western blot 
assays. Although the total 4E-BP1 expression was found 
to be enhanced in transgenic mouse livers a significant 
phosphorylation increase of 4E-BP1 in cT and cNT mouse 
hepatocytes was observed (Figure 3D and 3E). Shutdown 
of 4E-BP1 phosphorylation was observed in core primary 
mouse hepatocytes upon treatment with MEK/ERK and 
mTORC1 inhibitors, suggesting that these signaling 
pathways could be involved in the increase of 4E-BP1 
phosphorylation by HCV core protein (Supplementary 
Figure 2). 
Altogether these results corroborate the assumption 
that HCV, through core protein, enhances both total 
protein level and phosphorylation stoichiometry of 
4E-BP1 in hepatocytes of transgenic mouse livers. 
HCV core induces the expression of MTA1,  
a 4E-BP1 downstream target 
It has been reported that expression of a non 
phosphorylable 4E-BP1 mutant decreases YB1, vimentin, 
CD44 and MTA1 expressions at the protein but not 
mRNA level and thus could represent downstream targets 
of 4E-BP1 [21]. Among them, we chose to study MTA1 
expression because  this protein was reported to be 
highly expressed in HCC and served as an indicator of 
poor prognosis in HCC patients [22]. Our results show 
that increased expression of the phosphorylated forms 
of 4E-BP1induced by HCV core in HuH7 (Figure 4A) 
as well as in mouse livers was associated with a marked 
increase in MTA1expression (Figure 4B).  Consistent with 
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Figure 2: HCV core protein increases the level of phosphorylated 4E-BP1. (A) Immunoblotting analysis of 4E-BP1 
phosphorylation on Thr 37/46 in lysates of HuH7 controls (WT), HuH7 stably expressing core protein variants either isolated from 
tumor or non-tumor cirrhotic (cT or cNT) areas and HuH9.13 harboring the HCV NS3-NS5B subgenomic replicon and its related control 
(HuH9.13 cured). HCV NS5A and core expressions are shown. When the membrane was probed with an antibody directed against core 
antibody, an expected signal at 20 kDa was obtained in HuH7 cNT (white arrow), however this signal was observed at 25 kDa in HuH7 cT 
since they express a FLAG-tagged core (black arrow). (B) Graphic representation of average fold changes of phospho Thr37/46 4E-BP1 
normalized to 4E-BP1 (C, D) Protein lysates of HuH7 WT, cT, cNT, HuH9.13 cured and HuH9.13 were analyzed by Western blotting for 
the phosphorylation state of 4E-BP1 at Ser 65 and Thr 70, respectively. (E) Immunoblotting analysis of 4E-BP1 phosphorylation at Thr 
37/46 and the relative ratios of p4E-BP1/4E-BP1 in HuH7.5 replicon, harboring all HCV proteins. (F, G) Protein extracts of HuH7.5.1 and 
primary human hepatocytes infected or not with the HCV strain JFH1 were immubloted with phospho Thr37/46 4E-BP1. Fold changes of 
p4E-BP1 over 4E-BP1 are shown, *p value < 0.05. One representative immunoblot out of three independent experiments is shown and p38 
was used as loading control.
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Figure 3: HCV core variants mediate 4E-BP1 phosphorylation in transgenic mouse livers. (A) Liver proteins extracted 
from 9-month-old WT, transgenic mice that specifically express HCV core protein isolated from tumor and non-tumor (cT or cNT) areas 
(4 different mice per group) were analyzed for phospho 4E-BP1 by immunoblot. (B) Quantification of phospho-4E-BP1 relative to 4E-BP1 
levels, *p value < 0.05. (C) Immunohistochemical staining of WT, cT and cNT liver biopsies. Liver slices were immunostained with p4E-
BP1 antibody and representative results are shown (magnification x40). (D) Protein lysates of primary mouse hepatocytes isolated from 
transgenic mouse livers expressing or not cT and cNT were analyzed by immunoblot with antibodies directed against phospho 4E-BP1. 
One representative experiment is shown and p38 is used as loading control. (E) Depiction of normalized densitometric values of phospho-
4E-BP1 over 4E-BP1 in primary mouse hepatocytes, *p value < 0.05. 
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these findings we have previously reported that another 
gene of this 4E-BP1 signature, vimentin was upregulated 
in hepatocytes expressing HCV core [4]. These data 
provide evidence of downstream molecular effects of 4E-
BP1 activation by HCV core.
HCV core protein cooperates with Myc in 
hepatocarcinogenesis
Previous reports have delineated a significant link 
between c-Myc and 4E-BP1 phosphorylation in Myc-
driven hematological cancers [23]. Since none of the core 
transgenic mice had developed malignant lesions, it was 
therefore relevant to uncover whether HCV core turns 
oncogenic in a cancer predisposed atmosphere.
Hence, transgenic mice expressing either HCV 
core protein cT or cNT were intercrossed with Myc 
transgenic mouse lines in which liver-specific expression 
of c-Myc driven by woodchuck hepatitis virus (WHV) 
regulatory sequences causes liver cancer in all animals 
[24]. Liver tumors were detected earlier in bitransgenic 
animals carrying either cT or cNT core transgenes when 
compared to simple Myc littermates (Figure 5). This 
earlier detection was significant for Myc/cNT (p = 0.003) 
and Myc/cT (p = 0.045) as compared to Myc/WT. It was 
equivalent in Myc/cNT and Myc/cT mice at 9 and 12 
months where all bitransgenic mice developed HCC, even 
though it was more pronounced in Myc/cNT in 3-month-
old mice. Moreover the total number of tumors was 
statistically increased (p = 0.034) without interaction of 
time (p = 0.759) in both Myc/cT or Myc/cNT bitransgenic 
mice compared to Myc simple transgenic mice and no 
significant difference was observed between the 2 core 
variants (p = 0.3).
To correlate the marked acceleration of the onset 
of hepatocarcinogenesis in double transgenic mice Myc/
cT and Myc/cNT to 4E-BP1 status, further analysis of 
4E-BP1 phosphorylation state in 3-month-old mouse 
liver extracts was performed by Western blotting. 
Figure 6A and 6B show a representative immunoblotting 
of 4 different mouse liver extracts per group and indicate 
that both HCV core variants triggered 4E-BP1 hyper-
phosphorylation in double transgenic Myc/cT and Myc/
cNT mouse livers compared to Myc/WT littermates. This 
finding was sustained by immunohistochemical analysis 
of paraffin-embedded double transgenic mouse livers 
using phospho-4E-BP1 (Thr37/46) (Figure 6C). A more 
pronounced increase in the phosphorylation level of 
4E-BP1 was observed in double transgenic mice 
expressing both HCV core and Myc proteins suggesting 
that 4E-BP1 phosphorylation could be a possible effector 
of HCV core induced acceleration of HCC development. 
Next, we sought to track 4E-BP1 phosphorylation 
in liver tumors, thus Western blotting assays were 
performed on liver extracts from double transgenic liver 
tumors (T) and the adjacent non-tumor tissues (NT). 
Since tumor detection appeared later in Myc/WT than in 
Myc/cT and Myc/cNT mice, liver extract from 9-month-
old mice were used to compare 4E-BP1 phosphorylation 
in the 3 experimental conditions. In agreement with the 
immunoblotting results of the upper panels, Figure 6D 
shows that both variants of HCV core significantly induced 
4E-BP1 phosphorylation in NT tissues of Myc/core mouse 
livers as compared with Myc/WT. Furthermore, 4E-BP1 
phosphorylation was more enhanced in liver tumors of 
all double transgenic mice when compared with non-
tumorous surrounding counterparts. This increased 
4E-BP1 phosphorylation was also observed in the tumors 
Figure 4: HCV core induces the expression of MTA1, a 4E-BP1 downstream target. (A) Immunoblotting analysis of MTA1 
expression in lysates of HuH7 controls (WT), HuH7 stably expressing core protein variants either isolated from tumor or non-tumor 
cirrhotic (cT or cNT) areas and HuH9.13 harboring the HCV NS3-NS5B subgenomic replicon and its related control (HuH9.13 cured). (B)
Liver proteins extracted from 9-month-old WT, transgenic mice that specifically express HCV core protein isolated from tumor and non-
tumor (cT or cNT) areas (4 different mice per group) were analyzed for MTA1 expression by immunoblot.
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of Myc/WT mice suggesting a role of this phosphorylation 
in the context of Myc-induced cancerogenesis as 
previously reported [23].
Altogether, the present data indicate that HCV core 
protein and Myc act synergistically to induce hepatic 
tumor development. This correlates with an enhancement 
of 4E-BP1 phosphorylation on Thr37 and Thr46 that might 
serve as a priming oncogenic event.
DISCUSSION
HCV core protein orchestrates a complex and 
dynamic interaction network with cellular proteins 
involved in signal transduction, transcription, nucleic 
acid binding, apoptosis, cell cycle, cytoskeleton and 
kinase activity [25]. Herein, a phosphoproteomic study 
was conducted to decipher the signaling pathways 
activated by HCV core in hepatoma cells. Most of the 
identified phosphorylated proteins could be clustered in 
the above-mentioned processes such as lipid homeostasis, 
cytoskeleton dynamics and interestingly translation 
initiation machinery. Indeed, different phosphosites 
identified in this phosphoproteomic study (eIF4B, 4E-BP1, 
4E-BP2) are parts of different eukaryotic initiation factors 
that govern translational machinery. 4E-BP1 represents 
a master regulator of protein synthesis control that is 
often deregulated in cancer cells. It was reported that 
activation of the 4E-BP1/eIF4E axis selectively stimulates 
the expression of malignancy-related mRNAs [26] and 
phosphorylation of 4E-BP1 enables cancer cell survival 
by enhancing protein synthesis capacity. Validation of 
phosphoproteomic data by immunoblotting indicated that 
indeed, phosphorylation levels of 4E-BP1 were increased 
in HuH7 cells, primary mouse hepatocytes expressing 
either HCV cT or cNT core proteins and in HuH7.5.1 cells 
and primary human hepatocytes infected with the HCV 
strain JFH1. The same results were obtained when total 
livers of HCV cT or cNT transgenic mice were examined 
indicating that HCV core influences the phosphorylation 
status of 4E-BP1 in vivo. Increased expression of MTA1 in 
HuH7 or mouse livers expressing HCV cores supports the 
notion that core-induced 4E-BP1 phosphorylation leads to 
activation of at least some of 4E-BP1downstream targets.
Both cT and cNT variants exhibit the same capacity 
to increase the phosphorylation of 4E-BP1. However, it 
is interesting to note that the core cT is less expressed 
Figure 5: HCV core protein accelerates Myc-induced carcinogenesis in double transgenic mice. (A) Gross images of Myc/
WT, Myc/cT and Myc/cNT transgenic mouse livers. (B) Graphical representation of the percentage of tumor incidence and the total number 
of tumors in all transgenic mouse groups at 3, 6, 9 and 12 months, *p value < 0.05. 
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than cNT in all cell lines tested and that the cT protein 
expression is barely detected in vivo reflecting the 
expression level which is observed in infected human 
tissues. This implies that a weak expression of the cT is 
as effective as the highly expressed cNT, underlying the 
importance of core genetic variability and expression in 
mediating downstream responses.
The important finding of this study lies in the 
significant potentiation of tumor development when HCV 
core is expressed in oncogenic context. Indeed, the onset 
Figure 6: HCV core increases 4E-BP1 phosphorylation level in Myc/cT and Myc/cNT mouse livers. (A) Representative 
immunoblotting assay of phospho 4E-BP1 on proteins extracted from livers of 3-month-old simple Myc/WT or double transgenic, Myc/cT 
and Myc/cNT mice (4 different mice/group). (B) Average fold changes of densitometric values of phospho Thr37/46 4E-BP1 expression 
relative to 4E-BP1 levels are represented graphically, *p value < 0.05. (C) Immunohistochemical analysis of tissue slices from paraffin-
embedded livers of simple Myc/WT or double transgenic mice, Myc/cT and Myc/cNT, using phospho-4E-BP1 (magnification x40). 
(D) Protein extracts from double transgenic liver tumors (T) and the adjacent non-tumor tissues (NT) of 9-month-old Myc/WT, Myc/cT 
and Myc/cNT were analyzed for phospho-4E-BP1. One representative immunoblot of three independent experiments is shown, p38 is used 
as loading control.
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and the higher number of tumors were observed in Myc/
HCV core double transgenic mice when compared to 
single Myc littermates. Thus, cooperation with a cellular 
oncogene was required to reveal the oncogenicity of HCV 
core, since no malignancy was observed in our simple 
transgenic animal models. This novel function of HCV 
core acting as Myc tumor promoter in liver tumorigenesis 
is in accordance with the assumption that HCV core is 
a tumor accelerator in chemically induced HCC in DEN 
treated transgenic mice [27, 28]. 
Although many reports associated the 4E-BP1/
eIF4E axis to the development of different cancers, 
4E-BP1 phosphorylation in HCV core transgenic mice 
was not sufficient to initiate carcinogenesis and thus 
subsequent oncogenic alterations were required to 
drive oncogenesis. This is consistent with the obtained 
results in HCV core/Myc double transgenic mice. In 
accordance with our results, it was recently reported 
that activation of the 4E-BP1/eIF4E axis alone was not 
able to promote malignant transformation of murine 
hepatocytes, but that eIF4E cooperates with activated 
N-Ras to induce liver tumor development in mice [19]. 
Furthermore, in a Eμ-Myc transgenic mouse model 
in which constitutive overexpression of Myc in the 
B-cell compartment drives lymphomagenesis, it was 
reported that Myc overexpression results in 4E-BP1 
hyperphosphorylation that was maintained during tumor 
progression and was required for cancer cell survival 
in Myc-dependent tumor initiation and maintenance 
[23]. Moreover the 4E-BP1/eIF4E axis was reported as 
a key event in Myc lymphomagenesis since 4E-BP1-
dependent inhibition of eIF4E activity impedes Myc-
driven lymphomas [29]. In our model, 4E-BP1 was 
found to be hardly phosphorylated in non-tumor tissues 
from Myc/WT mice, but this phosphorylation level was 
greatly increased in tumor tissue. This is consistent 
with the findings that in WHV/Myc transgenic mice, 
Myc is transiently overexpressed in the liver after 
birth, and it is re-expressed at tumor onset [24]. More 
importantly, phosphorylated 4E-BP1 abundance was 
observed in non-tumor tissue of Myc/cT and Myc/
cNT double transgenic and this phosphorylation was 
more pronounced in the tumors. It must be noted that, 
although in these transgenic mice the ratio between 
p4E-BP1/4E-BP1 was statistically significant, the total 
forms of 4E-BP1 were increased as compared to control 
mouse livers. Thus, as 4E-BP1 has been reported 
to be upregulated in many cancers it is possible that 
the non phosphorylated form plays also a role in the 
development of Myc-induced HCC.
Altogether our data clearly establish that 4E-BP1 
expression and phosphorylation are important targets 
for HCV core-related effects. Furthermore this study 
reinforces the notion that HCV core may potentiate 
oncogenes by acting as a cooperating partner, in particular 
in c-Myc-induced liver carcinogenesis.
MATERIALS AND METHODS
Reagents 
Antibodies: 4E-BP1 (9452), phospho(Thr37/46) 
4E-BP1 (2855), phospho(Ser65) 4E-BP1 (9451), 
phospho(Thr70) 4E-BP1 (9455), p44/42-MAPK (9102), 
phospho(Thr202/Tyr204) p44/42-MAPK (9101) and 
MTA1 (5647) were purchased from Cell Signaling, Core 
(sc-52403) and p38 (C-20, sc-535) provided from Santa 
Cruz. NS5A (ab13833) was from Abcam. Inhibitors: 
Rapamycin (9904) and PD0325901 (PZ0162) were 
purchased from Cell Signaling and Sigma, respectively.
Transgenic mice 
HCV core and WHV/c-Myc transgenic mice [24] 
were maintained in a pathogen-free facility, fed, and 
monitored in agreement with protocols approved by the 
guidelines of the Ministère de l’Agriculture (France). 
WHV/c-Myc transgenic mice, in which liver-specific 
expression of c-Myc is driven by woodchuck hepatitis 
virus (WHV) regulatory sequences, were previously 
described [24]. To establish HCV core transgenic mice, 
genotype 1b core cDNAs isolated from tumor (T) or 
cirrhotic nodules (NT) from the same patient were cloned 
downstream of hepatitis B virus regulatory element and 
microinjected into mouse embryos from the C57BL/6 
(Institut Clinique de la Souris, Strasbourg, France). Both 
HCV core sequences, cT and cNT, were verified and 
correspond to previously published ones [3].
Homozygotes WHV/c-Myc transgenic mice were 
crossed with either homozygotes core T, core NT or 
C57BL/6 mice. The F1 were identified by hybridization 
of tail cDNA with WHV c-Myc and core probes. At least 
10 mice per group were analyzed. Since it was previously 
shown that HCC development was more prominent in 
males, only males were selected in this study.  
Double and single transgenic mice were euthanized 
at 3, 6, 9 or 12 months and livers were examined for 
tumor size and number. Tumor samples and adjacent liver 
tissues were fixed in 4% paraformaldehyde and embedded 
in paraffin for histopathological examination. For protein 
analysis, tumor samples were dissected free of adjacent 
liver tissues, capsule and necrosis, snap-frozen in liquid 
nitrogen and kept at –80°C. Livers from nontransgenic 
C57BL/6, mice were used as controls.
Cell culture and viral infection
The hepatoma cell line HuH7 was obtained from 
ATCC. HuH7 cT and HuH7 cNT cells stably express 
HCV core protein variants isolated from tumor or non-
tumor cirrhotic areas, respectively. HuH7.5 replicon cells 
express all HCV proteins. HuH9.13 cell line harbors 
the HCV NS3-NS5B subgenomic replicon. HuH9.13 
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cured cell line was obtained from HuH9.13 after 1month 
treatment with 500 U/ml interferon α2a as described [30]. 
HuH7.5.1 cells were gift from F.V. Chisari, the Scripps 
Research Institute, La Jolla, CA, USA [31]. All cell lines 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum and 
penicillin/streptomycin at 37°C in a humidified 5% CO2 
atmosphere.
Primary hepatocytes of HCV core transgenic mice 
were isolated by in situ collagenase perfusion of livers as 
previously described [4].
Human primary hepatocytes freshly isolated from 
HCV-seronegative adult patients were purchased from 
Biopredic (Rennes, France) and maintained in primary 
culture at 37°C in a humidified 5% CO2 atmosphere 
as described previously [32]. Briefly, primary human 
hepatocytes were resuspended in complete medium 
consisting of Leibovitz’s L-15 medium (Invitrogen, Cergy 
Pontoise, France) supplemented with 26 mM NaHCO3, 
100 µg/ml streptomycin, 100 U/ml penicillin, 100 IU/l 
insulin (Novo Nordisk, Bagsvaerd, Denmark) and 10% 
heat-inactivated FCS, and seeded onto 6-well plates pre-
coated with calf skin type I collagen (Sigma-Aldrich) 
at a density of 1.6 × 105 viable cells/cm2. The medium 
was replaced 16 h later with fresh complete medium 
supplemented with 1 μM hydrocortisone hemisuccinate 
(SERB, Paris, France), and cells were left in this medium 
until HCV inoculation 2 days later. A high-titre stock of 
JFH1-HCV [33] was produced as described previously 
[32]. HuH7.5.1 cells and primary human hepatocytes 
were inoculated at a multiplicity of infection of 0.2 and 2, 
respectively. The culture medium was replaced with the 
inoculum diluted in the smallest volume of fresh medium 
sufficient for covering the cells. The inoculum was 
removed after a 4-hour incubation, then cells were washed 
3 times with phosphate-buffered saline and maintained in 
their respective complete medium for 3 (HuH7.5.1 cells) 
or 6 (primary human hepatocytes) days before lysis for 
Western blot analysis.
Stable isotope labelling with aminoacids in cell 
culture and phosphopeptide enrichment
Metabolic labelling was performed using the 
SILAC approach where HuH7 cells, or HuH7 cells 
stably expressing HCV cT protein were cultured either 
in light, medium or heavy SILAC media. Inversion of 
SILAC labeling allowed us to compare three independent 
experiments while avoiding possible labeling biases. Cells 
were cultured in DMEM supplemented with 10% dialyzed 
fetal bovine serum, 50 mg l-proline, and either l-arginine 
(Arg0) and l-lysine (Lys0) (light medium), or 13C6
14N4-l-
arginine (Arg6) and 4,4,5,5-D4-l-lysine (Lys4) (medium 
medium), or 13C6
15N4-l-arginine (Arg10) and 
13C6
15N2-l-
Lysine (Lys8) (heavy medium) (Thermo Scientific). Cells 
were maintained in culture for at least five doublings 
and the efficiency of labeling was confirmed by MS/MS 
analysis.  
Whole cell protein extracts were obtained by lysing 
cells in a RIPA lysis buffer containing 50 mM Tris-
HCl pH 7.4, 1% NP-40, 150 mM NaCl, 0.25% sodium 
deoxycholate, 0.5% SDS, Benzon nuclease (Novagen), 
a protease inhibitor cocktail and phosphatase inhibitors 
(Roche). Total cellular protein extracts were precipitated 
with TCA/acetone and then resuspended in 8M urea in 
100 mM triethylammonium bicarbonate (TEAB) pH 
8.5. A Bradford assay was performed to equalize protein 
concentrations for subsequent 1:1:1 ratio mixing of the 
three lysates. Mixed lysates were reduced by 10 mM Tris 
(2-carboxyethyl)phosphine (TCEP) for 1h at 37°C and 
then alkylated by 20 mM methylmethanethiosulfonate 
(MMTS) for 30 min at room temperature. After 7-fold 
dilution in 100 mM TEAB, proteins were digested 
overnight with sequencing grade trypsin (Promega) at 
an enzyme/protein ratio of 1/100 (w/w) at 37°C. The 
total peptide mixtures were then acidified to ~pH 3 
using acetic acid (AA), desalted on a C18 spin columns 
(Harvard Apparatus) and eluted in 60% ACN, 3% 
AA. This eluate was diluted 1:1 with water to reach a 
composition of 30% ACN, 1.5% AA, compatible with 
phosphopeptide enrichment. Desalted peptides were 
enriched for phosphopeptides by incubation with 10 uL of 
packed IMAC beads (Sigma-Aldrich) for 2h on a wheel 
rotating at 15 rpm. After washing the beads three times 
with 30% ACN, 1.5% AA, phosphopeptides were eluted 
from the IMAC resin using the alkaline buffer 400 mM 
NH4OH. Eluates were neutralized with 10% AA and dried 
by vacuum centrifugation [34]. Finally, phosphopeptides 
were resuspended in 5% ACN, 0.1% formic acid (FA) for 
subsequent analysis by LC-MS/MS.
Liquid chromatography and mass spectrometry
Phosphopeptide separation was performed on an 
Ultimate 3000 nano LC system (Dionex) equipped with 
a C18 column (Acclaim PepMap C18, 75 μm id × 15 
cm length, 3 μm particle size, 100 Å porosity, Dionex) 
and online connected to an LTQ Orbitrap XL mass 
spectrometer equipped with an ETD (Electron Transfer 
Dissociation) module (Thermo-Fisher Scientific). The 
mobile phases consisted of solvents A = 5% ACN (v/v), 
0.1% FA (v/v) in water and B = 80% ACN (v/v), 0.1% 
FA (v/v) in water. Phosphopeptides were separated at a 
flow rate of 0.3 μL/min using a linear gradient of 60 min 
ramping from 0 to 50% of solvent B followed by an 
increase to 100% of solvent B in 10 min. The column 
was finally washed with 100% of solvent B for 10 min 
followed by re-equilibration with solvent A for 30 min. 
Column eluent was sprayed into the MS instrument 
operated with a lock mass of 445.1200 for more accurate 
mass measurements in FTMS mode. Survey spectra 
were acquired over the mass range m/z 400–1400 at a 
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resolution of 30,000 in the Orbitrap cell. In two separate 
runs, MS/MS data were acquired in data-dependent mode 
by selecting from the FTMS spectra the six most intense 
precursor ions for fragmentation by collision induced 
dissociation (CID) or electron transfer dissociation 
(ETD). Former target ions selected for MS2, within a mass 
window of +/- 5 ppm, were dynamically excluded for 
45s. In CID fragmentation mode, Multistage Activation 
(MSA) was applied, while considering the possible neutral 
losses of 32.67, 49.00, 65.33 and 98.00 to account for 
singly and doubly phosphorylated peptides [35]. In CID, 
only species of charge states 2+ and 3+ were selected 
for fragmentation; in ETD, those of charge states 2+ and 
above were selected. For ETD, fluoranthene was used 
as the electron donor. A supplemental activation was 
systematically applied at 20% to increase fragmentation 
efficiency. Peptides were fragmented after accumulating 
ions to a target value of 2.105, with a maximum injection 
time of 500 ms and using a charge state dependent reaction 
time (following the formula: RT = 100 ms × 2/z, with z the 
precursor charge state). 
Assigning peptide sequences to MS/MS spectra 
and relative quantification 
Raw spectra were searched against the human 
SwissProt protein database (released on July 30th 2013) 
using the Andromeda search engine implemented in 
the MaxQuant software (version 1.3.0.5) that includes 
features for SILAC-based quantitation and phosphosite 
localization. The SILAC label modifications and 
methylthio (C) for cysteine residues were set as fixed 
modifications in the database search. Methionine 
oxidation and phosphorylation on S, T and Y residues 
were added as variable modifications. The precursor 
and fragment ion mass tolerances were 5 ppm and 0.6 
Da, respectively. Up to two missed cleavages were 
allowed for trypsin digestion and the false discovery 
rate (FDR) was set to 1% for both peptide and protein 
identifications. 
High precision SILAC-based quantitation of 
proteins was achieved by MaxQuant in a fully automatic 
way. Peaks are detected in each MS scan, peptide hills 
over the m/z-retention time are taken into account for 
intensity integrations and ratio calculation.
Phosphorylation site localization was based on PTM 
scores [36] that assign probabilities for each possible 
amino acid and then allow grouping the phosphosites 
into three categories. Probability scores greater or equal 
to 0.75 were considered to allow definite phosphosite 
localization, scores smaller than 0.75 and greater or 
equal to 0.5 corresponded to ambiguously localized 
phosphosites, whereas scores smaller than 0.5 were 
indicated non-localized phosphosites. This proteomic 
approach applied to the cellular models in three 
independent SILAC experiments led to the identification 
of 1308 phosphopeptides differing by their amino acid 
sequence corresponding to an overall of 977 different 
proteins. Phosphopeptides showing abundance ratios 
core/WT greater than 1.96 standard deviations distant 
from the mean in at least two out of the three biological 
experiments, were considered to be significantly hyper-
phosphorylated. 
Western blot analysis
Protein extracts were subjected to SDS-PAGE gels 
and transferred onto nitrocellulose membranes. The blots 
were probed with different antibodies according to the 
manufacturer’s instructions. Experiments were repeated 
three times and signal quantification was performed using 
Genetools software. 
Immunohistochemistry
Immunohistochemical staining on mouse liver 
slices was performed on 4% paraformaldehyde-
fixed, paraffin-embedded tissues. Deparaffinized 
sections were incubated in 3% hydrogen peroxide for 
20 minutes to quench the endogenous peroxidase. For 
antigen retrieval, slides were treated in citrate buffer 
for 10 minutes and incubated overnight with rabbit 
phospho(Thr37/46) 4E-BP1 at 1/1500 dilution in PBS, 
followed by an incubation with HRP-labeled secondary 
antibody (Dako Envision Systems) for 30 minutes. 
Immunoperoxidase staining was carried out with 
diaminobenzidine.
Statistical analysis
The total number of tumors was analyzed by a 
Fisher test using a 2-way ANOVA: variance analysis 
integrated 2 factors (time and transgenic mouse group). 
Interaction between these 2 factors was excluded on the 
basis of Myc/WT control mice. LSD (post Hoc) test was 
performed after Fisher test to discriminate significance 
of each capsid group as compared to controls Myc/WT. 
Comparisons between two groups were performed with 
t test, (*) p value < 0.05.
Quantitative RT-PCR
Frozen liver tissues were homogenized using 
Precellys (Ozyme) in cell-lysis grinding buffer and total 
RNA was isolated using RNAeasy kit (Qiagen), according 
to the manufacturer’s instructions. Total RNAs were 
subjected to RNase-free DNase (Ambion) and converted 
into cDNA by using a Revert Aid Premium First Strand 
(Fermentas) and qPCR with Light Cycler Fast Start DNA 
green master (Roche Diagnostics). HPRT was used as 
housekeeping gene and relative quantification was based 
on the 2-ΔΔCT method . 
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